The stock of BioTime, Inc. (NYSEMKT:BTX) is a huge mover today! About 156,646 shares traded hands. BioTime, Inc. (NYSEMKT:BTX) has risen 9.00% since April 28, 2016 and is uptrending. It has outperformed by 3.07% the S&P500.
The move comes after 9 months positive chart setup for the $325.69 million company. It was reported on Dec, 1 by Barchart.com. We have $3.32 PT which if reached, will make NYSEMKT:BTX worth $9.77M more.
Analysts await BioTime, Inc. (NYSEMKT:BTX) to report earnings on March, 21. They expect $-0.18 EPS, down 12.50% or $0.02 from last year’s $-0.16 per share. After $-0.08 actual EPS reported by BioTime, Inc. for the previous quarter, Wall Street now forecasts 125.00% negative EPS growth.
According to Zacks Investment Research, “BioTime, Inc. is a clinical-stage biotechnology company focused on developing and commercializing novel therapies in the field of regenerative medicine. The foundation of its core therapeutic technology platform is pluripotent cells that are capable of becoming any of the cell types in the human body. BioTime’s research and other activities have resulted, over time, in the creation of other subsidiaries that address other non-therapeutic market opportunities such as cancer diagnostics, drug development and cell research products, and mobile health software applications.”
Insitutional Activity: The institutional sentiment increased to 2.67 in 2016 Q2. Its up 0.42, from 2.25 in 2016Q1. The ratio increased, as 3 funds sold all BioTime, Inc. shares owned while 13 reduced positions. 9 funds bought stakes while 27 increased positions. They now own 38.13 million shares or 10.80% more from 34.42 million shares in 2016Q1.
Blackrock Inv Management Llc holds 232,927 shares or 0% of its portfolio. Barclays Public Ltd Com holds 0% or 998 shares in its portfolio. Destination Wealth Mgmt last reported 591,245 shares in the company. Tiaa Cref Invest Management Llc accumulated 206,408 shares or 0% of the stock. California State Teachers Retirement last reported 134,039 shares in the company. Deutsche Retail Bank Ag owns 32,074 shares or 0% of their US portfolio. Morgan Stanley, a New York-based fund reported 10,538 shares. Principal Fincl Group Inc Incorporated accumulated 0% or 11,249 shares. Williams Jones Assocs Ltd Liability Company reported 60,450 shares or 0.01% of all its holdings. Gluskin Sheff & Associate last reported 0% of its portfolio in the stock. Blackrock Grp Ltd last reported 37,580 shares in the company. Great West Life Assurance Can has invested 0% of its portfolio in BioTime, Inc. (NYSEMKT:BTX). The New York-based Teachers Advsr has invested 0% in BioTime, Inc. (NYSEMKT:BTX). Family Mngmt holds 0.14% of its portfolio in BioTime, Inc. (NYSEMKT:BTX) for 93,500 shares. D E Shaw & Com last reported 16,615 shares in the company.
More notable recent BioTime, Inc. (NYSEMKT:BTX) news were published by: Businesswire.com which released: “BioTime, Inc. to Report Second Quarter Results on August 9, 2016” on July 27, 2016, also Businesswire.com with their article: “Adjustments Affecting BioTime, Inc. Common Share Purchase Warrants Expiring …” published on January 12, 2016, Quotes.Wsj.com published: “News BioTime Inc.BTX” on February 12, 2011. More interesting news about BioTime, Inc. (NYSEMKT:BTX) were released by: Businesswire.com and their article: “BioTime, Inc. Announces Proposed Public Offering of Common Stock” published on June 15, 2016 as well as Businesswire.com‘s news article titled: “BioTime, Inc. Announces Full Exercise and Closing of Underwriters’ Over …” with publication date: July 05, 2016.
BTX Company Profile
BioTime, Inc., incorporated on November 30, 1990, is a clinical-stage biotechnology company. The Firm is focused on the field of regenerative medicine, specifically pluripotent stem cell technology. The Firm is engaged in the research and development of therapeutic products for oncology, orthopedics, retinal and neurological diseases and disorders, blood and vascular system diseases and disorders, blood plasma volume expansion, diagnostic products for the early detection of cancer, and hydrogel products that may be used in surgery and products for human embryonic stem cell research. Regenerative medicine refers to therapies based on stem cell technology that are designed to rebuild cell and tissue function lost due to degenerative disease or injury. The Company’s pluripotent stem cell technology is complemented by its HyStem technology for the delivery and engraftment of cells, whether derived from pluripotent stem cells or the patient’s own somatic or adult stem cells, at the desired location.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.